Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GATE-101 in Healthy Volunteers
NCT04618263Phase 1Terminated
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GATE-101 in major depressive disorder (MDD) and Hypersomnia (HS) (12 arms). Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events at 28 Days. Started Oct 2020; status: terminated.
02
Drugs
GATE-101
03
Conditions
major depressive disorder (MDD)Hypersomnia (HS)
Beyond the preview
Go deeper on NCT04618263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04618263.